II

Night Vision Device Market worth $11.2 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, October 19, 2023
RTX, Video content analysis, NVD, Monitor, II, Building inspection, Region, IR, BAE Systems, Teledyne Technologies, Aviation, Law enforcement, Storage device, Night vision, MAK Technologies, Inc., Hunting, Safety, VMS, Overalls, Investment, IP, Mobile device, Telescopic sight, Analog, Modularity

Portable night vision devices are experiencing increasing demand due to a range of driving factors.

Key Points: 
  • Portable night vision devices are experiencing increasing demand due to a range of driving factors.
  • The increasing population and need for security and surveillance in these countries are projected to drive the night vision devices market during the forecast period.
  • The night vision devices market in Asia Pacific is expected to record the highest CAGR during the forecast period.
  • China, Japan, and India are among the major countries driving the night vision devices market in the region.

Crayfish BidCo has agreed conditional purchases of further Caverion shares which will, after FCCA approval, fulfill acceptance condition under tender offer; update on FCCA process

Retrieved on: 
Wednesday, October 18, 2023
BY, Finnish Financial Supervisory Authority, Tender offer, Tender, FOR, II, Consumer, Treasury, AFRICA, Varma Mutual Pension Insurance Company, NOT, Finnish Competition and Consumer Authority, Offer and acceptance, FCCA, Cryptocurrency, Security (finance), Pharmaceutical industry, Triton, Caverion

HELSINKI, Oct. 18, 2023 /PRNewswire/ -- Crayfish BidCo Oy has today published the following information through a stock exchange release:

Key Points: 
  • Together with the Offeror's current shareholding, the Shares to be acquired under the Conditional Share Purchases represent approximately 67.77 percent of all outstanding shares (excluding treasury shares) in Caverion, which exceeds the minimum acceptance condition of more than two-thirds (2/3) of all Shares under the Tender Offer.
  • Once the Divestment Commitment has been fulfilled, all regulatory approvals necessary for the completion of the Tender Offer will have been obtained.
  • At the same time, we have successfully concluded the FCCA's phase II investigation and received conditional merger control clearance for our tender offer in Finland.
  • The Offeror currently expects that the supplement to the Tender Offer Document will be published during October 2023.

TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Retrieved on: 
Thursday, October 12, 2023
RMS, Treatment, MD, Multiple sclerosis, Therapy, II, Research, TG, Publication, Patient, Pharmaceutical industry

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy.

Key Points: 
  • NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy.
  • A link to the presentation is included below.
  • Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We continue to be impressed by the exploratory analyses of BRIUMVI in multiple sclerosis and look forward to continuing to share additional data from both the ULTIMATE trials as well as ENHANCE.”
    Lead Author: John Foley, MD - Rocky Mountain Multiple Sclerosis, Salt Lake City, UT, USA
    The above presentation is also available within the Publications section of the Company’s website at www.tgtherapeutics.com/publications.cfm.

TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Retrieved on: 
Wednesday, October 11, 2023
RMS, MS, Treatment, Maintenance, MD, Multiple sclerosis, Therapy, IV, II, Research, TG, Publication, Patient, Pharmaceutical industry

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy.

Key Points: 
  • NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy.
  • A link to each presentation is included below.
  • Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “The exploratory data from the ULTIMATE I & II trials evaluating BRIUMVI in patients with relapsing forms of MS continues to be exciting and highlights the unique attributes of BRIUMVI.
  • Today at the ECTRIMS annual meeting, we were also excited to present the first data from the ENHANCE trial evaluating patients who switch from an IV anti-CD20 antibody to BRIUMVI.”
    ePoster Presentation Title: Evaluating the Maintenance of Efficacy and Tolerability when Transitioning from IV anti-CD20 Therapy to Ublituximab: ENHANCE Study Design, Patient Demographics and Preliminary Data
    Lead Author: John Foley, MD - Rocky Mountain Multiple Sclerosis, Salt Lake City, UT, USA
    The above referenced presentations are also available within the Publications section of the Company’s website at www.tgtherapeutics.com/publications.cfm.

Fiber Optics Market to increase by USD 3.6 billion from 2022 to 2027 | Rising smart city initiatives drive the market - Technavio

Retrieved on: 
Tuesday, October 17, 2023
Geography, Leoni AG, Fiber to the x, Nexans, Belden Incorporated, Corning Inc., Hitachi, Internet, USD, Communication, Computer network, Telecom, HFCL, Growth, II, Glass, PON, Panzer corps, YOY, Nature, Sterlite Technologies, Mobile phone

NEW YORK, Oct. 16, 2023 /PRNewswire/ -- The fiber optics market size is expected to grow by USD 3.6 billion between 2022 and 2027.

Key Points: 
  • NEW YORK, Oct. 16, 2023 /PRNewswire/ -- The fiber optics market size is expected to grow by USD 3.6 billion between 2022 and 2027.
  • Explore detailed information by purchasing a report
    Rising smart city initiatives are notably driving market growth Fiber optics forms an essential part of smart city initiatives, playing a pivotal role in enabling various applications that aim to transform cities into more connected and intelligent environments.
  • The report analyses the market size and growth and provides accurate predictions on the growth of the market.
  • The passive optical network (PON) market size is projected to increase by USD 25.89 billion by 2026, accelerating at a CAGR of 19.42%.

FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery

Retrieved on: 
Tuesday, October 17, 2023
Oncology, Health, FDA, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, MSD, Congress, III, Hepatitis, HIV disease progression rates, Immunosuppression, MRK, NYSE, Lung cancer, Food, Platinum, American Joint Committee on Cancer, Pembrolizumab, The New England Journal of Medicine, AJCC, OS, PD-L1, Colitis, EGFR, Stanford University, Medicine, Pemetrexed, Patient, ESMO, Merck & Co., Steroid, EFS, II, Carboplatin, TPS, Pneumonitis, Paclitaxel, History, Head, International Association, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, European Society for Medical Oncology, Neoplasm, Hematopoietic stem cell transplantation, European Society of Gynaecological Oncology, T2A, ALK, Nephritis, Pharmaceutical industry, Vaccine, NSCLC, Merck

With this approval, KEYTRUDA has six indications in NSCLC, across both metastatic and earlier stages of NSCLC.

Key Points: 
  • With this approval, KEYTRUDA has six indications in NSCLC, across both metastatic and earlier stages of NSCLC.
  • The EFS results, which were from the first interim analysis, were published in June 2023 in the New England Journal of Medicine.
  • Adverse reactions occurring in patients with resectable NSCLC receiving KEYTRUDA in combination with platinum-containing chemotherapy, given as neoadjuvant treatment and continued as single agent adjuvant treatment, were generally similar to those occurring in patients across tumor types receiving KEYTRUDA in combination with chemotherapy.
  • Eighty-one percent of patients in the KEYTRUDA in combination with platinum-containing chemotherapy arm had definitive surgery compared to 76% of patients in the placebo in combination with platinum-containing chemotherapy arm.

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Retrieved on: 
Monday, October 16, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, DFS, MRK, NYSE, Lung cancer, American Joint Committee on Cancer, European Directive on Traditional Herbal Medicinal Products, Death, NSCLC, Rated R, AJCC, Committee for Medicinal Products for Human Use, Risk, European Commission, Recurrence, Disease, Merck & Co., Immunotherapy, EC, II, Marketing, Committee, Civil service commission, Face, Patient, Pharmaceutical industry, Merck, EU

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a monotherapy for the adjuvant treatment of adults with non-small cell lung cancer (NSCLC) who are at high risk of recurrence following complete resection and platinum-based chemotherapy.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a monotherapy for the adjuvant treatment of adults with non-small cell lung cancer (NSCLC) who are at high risk of recurrence following complete resection and platinum-based chemotherapy.
  • This approval by the EC follows the positive recommendation from the Committee for Medicinal Products for Human Use received in September 2023 and was based on results from the Phase 3 KEYNOTE-091 trial.
  • At a median follow up time of 46.7 months, KEYTRUDA demonstrated a clinically meaningful improvement in disease-free survival (DFS) in patients who received adjuvant chemotherapy, reducing the risk of disease recurrence or death by 24% (HR=0.76 [95% CI, 0.64-0.91]).
  • “We are proud that in Europe, KEYTRUDA now has five approved indications in non-small cell lung cancer, in both earlier and advanced stages of disease.”

Innate Pharma Announces Abstracts Selected for ESMO Congress 2023

Retrieved on: 
Monday, October 16, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Congress, IPHA, ESMO, European Society for Medical Oncology, Euronext Paris, II, Lung cancer, IPH, Patient, Pharmaceutical industry

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the following presentations will be presented at the European Society for Medical Oncology (ESMO) Congress 2023, taking place October 20-24 in Madrid, Spain.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the following presentations will be presented at the European Society for Medical Oncology (ESMO) Congress 2023, taking place October 20-24 in Madrid, Spain.
  • Abstract Title: A Phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell lung cancer (MATISSE)

Cadmus Awarded Multi-year, USAID ES3 Contract With $93 Million Total Ceiling

Retrieved on: 
Thursday, October 12, 2023
Data Analytics, Consulting, Data Management, Professional Services, Technology, Climate, Acquisition, United, GEMS, Private sector, CFR, Government, OASIS, Capacity building, ECOS, Economic development, II, FAA, International development, Social, Biophysical environment, Foreign Assistance Act, Knowledge management, USAID, Risk management, Agency

Winning ES3 highlights Cadmus’ ongoing role as the Agency’s leading safeguards support contractor.

Key Points: 
  • Winning ES3 highlights Cadmus’ ongoing role as the Agency’s leading safeguards support contractor.
  • This single-award, Agency-wide contract supports a consistent, quality approach to safeguards implementation across USAID, including implementing partner training and environmental officer backstopping support.
  • Cadmus will deliver via its dedicated in-house USAID safeguards support team, its in-house and global network of subject matter experts, and by bringing to USAID the full capabilities of its small business-centered ES3 team.
  • “We are incredibly proud that the Cadmus team has been awarded this contract to continue our environmental and social safeguards support for USAID,” said President and CEO Ian Kline.

The Inner Circle Acknowledges, John Ashley Sheldon, II as a Top Pinnacle Professional for his contributions to the field of Solar Energy

Retrieved on: 
Monday, October 16, 2023
Parent, Multimedia, Acquisition, Family, Mentorship, Business, Gardening, Music, Golf, Solar energy, Business intelligence, Education, Florida International University College of Business, Growth, II, Westinghouse, Philosophy, Business development, Bachelor of Business Administration, Business administration, Sales, Inner circle, Renewable energy

INDIAN LAND, S.C., Oct. 16, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, John Ashley Sheldon, II is acknowledged as a Top Pinnacle Professional for his contributions to the field of Solar Energy.

Key Points: 
  • INDIAN LAND, S.C., Oct. 16, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, John Ashley Sheldon, II is acknowledged as a Top Pinnacle Professional for his contributions to the field of Solar Energy.
  • Mr. Sheldon pursued higher education at Florida International University College of Business in 2008 where he earned a Bachelor of Business Administration.
  • With more than 15 years in the field, he is an expert in solar energy, particularly in residential solar installation and battery installation.
  • Finding immense success in the field, he founded his own solar marketing company, Sheldon's Solar Service, in 2010 and trademarked "SolarReady®".